Cargando…
Plant-derived compounds for treating autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic hereditary kidney disease, is the fourth leading cause of end-stage kidney disease worldwide. In recent years, significant progress has been made in delaying ADPKD progression with different kinds of chemical drugs, such...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479581/ https://www.ncbi.nlm.nih.gov/pubmed/37675342 http://dx.doi.org/10.3389/fneph.2023.1071441 |
_version_ | 1785101622236413952 |
---|---|
author | Zhang, Jieting Chen, Jiaxin Xu, Jing Xue, Cheng Mao, Zhiguo |
author_facet | Zhang, Jieting Chen, Jiaxin Xu, Jing Xue, Cheng Mao, Zhiguo |
author_sort | Zhang, Jieting |
collection | PubMed |
description | Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic hereditary kidney disease, is the fourth leading cause of end-stage kidney disease worldwide. In recent years, significant progress has been made in delaying ADPKD progression with different kinds of chemical drugs, such as tolvaptan, rapamycin, and somatostatin. Meanwhile, numerous plant-derived compounds have been investigated for their beneficial effects on slowing ADPKD progression. Among them, saikosaponin-d, Ganoderma triterpenes, curcumin, ginkgolide B, steviol, resveratrol, Sparganum stoloniferum Buch.-Ham, Cordyceps sinensis, triptolide, quercitrin, naringin, cardamonin, gambogic acid, and olive leaf extract have been found to retard renal cyst development by inhibiting cell proliferation or promoting cell apoptosis in renal cyst-lining epithelial cells. Metformin, a synthesized compound derived from French lilac or goat’s rue (Galega officinalis), has been proven to retard the progression of ADPKD. This review focuses on the roles and mechanisms of plant-derived compounds in treating ADPKD, which may constitute promising new therapeutics in the future. |
format | Online Article Text |
id | pubmed-10479581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104795812023-09-06 Plant-derived compounds for treating autosomal dominant polycystic kidney disease Zhang, Jieting Chen, Jiaxin Xu, Jing Xue, Cheng Mao, Zhiguo Front Nephrol Nephrology Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic hereditary kidney disease, is the fourth leading cause of end-stage kidney disease worldwide. In recent years, significant progress has been made in delaying ADPKD progression with different kinds of chemical drugs, such as tolvaptan, rapamycin, and somatostatin. Meanwhile, numerous plant-derived compounds have been investigated for their beneficial effects on slowing ADPKD progression. Among them, saikosaponin-d, Ganoderma triterpenes, curcumin, ginkgolide B, steviol, resveratrol, Sparganum stoloniferum Buch.-Ham, Cordyceps sinensis, triptolide, quercitrin, naringin, cardamonin, gambogic acid, and olive leaf extract have been found to retard renal cyst development by inhibiting cell proliferation or promoting cell apoptosis in renal cyst-lining epithelial cells. Metformin, a synthesized compound derived from French lilac or goat’s rue (Galega officinalis), has been proven to retard the progression of ADPKD. This review focuses on the roles and mechanisms of plant-derived compounds in treating ADPKD, which may constitute promising new therapeutics in the future. Frontiers Media S.A. 2023-02-03 /pmc/articles/PMC10479581/ /pubmed/37675342 http://dx.doi.org/10.3389/fneph.2023.1071441 Text en Copyright © 2023 Zhang, Chen, Xu, Xue and Mao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nephrology Zhang, Jieting Chen, Jiaxin Xu, Jing Xue, Cheng Mao, Zhiguo Plant-derived compounds for treating autosomal dominant polycystic kidney disease |
title | Plant-derived compounds for treating autosomal dominant polycystic kidney disease |
title_full | Plant-derived compounds for treating autosomal dominant polycystic kidney disease |
title_fullStr | Plant-derived compounds for treating autosomal dominant polycystic kidney disease |
title_full_unstemmed | Plant-derived compounds for treating autosomal dominant polycystic kidney disease |
title_short | Plant-derived compounds for treating autosomal dominant polycystic kidney disease |
title_sort | plant-derived compounds for treating autosomal dominant polycystic kidney disease |
topic | Nephrology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479581/ https://www.ncbi.nlm.nih.gov/pubmed/37675342 http://dx.doi.org/10.3389/fneph.2023.1071441 |
work_keys_str_mv | AT zhangjieting plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease AT chenjiaxin plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease AT xujing plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease AT xuecheng plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease AT maozhiguo plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease |